Varivax

Varivax is a vaccine used primarily to protect against the varicella zoster virus, the primary cause of chickenpox. It was developed by Merck & Co., and was first approved for use by the FDA in the United States in 1995.

History[edit | edit source]

The development of Varivax began in the late 1980s, when researchers at Merck began to investigate the possibility of creating a vaccine for chickenpox. The vaccine was approved for use in the United States in 1995, and has since been approved for use in many other countries around the world.

Composition[edit | edit source]

Varivax is a live, attenuated vaccine. This means that it contains a version of the varicella zoster virus that has been weakened so that it cannot cause disease in healthy individuals. The vaccine also contains small amounts of other ingredients, such as gelatin and neomycin, which are used to stabilize the vaccine and prevent contamination.

Administration and dosage[edit | edit source]

Varivax is administered by subcutaneous injection. The recommended dosage is two doses, with the first dose typically given at 12-15 months of age and the second dose at 4-6 years of age. However, the exact timing and number of doses may vary depending on the individual's age, health status, and other factors.

Efficacy and side effects[edit | edit source]

Studies have shown that Varivax is highly effective at preventing chickenpox. Most people who receive the vaccine will not get chickenpox, and those who do get the disease will typically have a milder case. Common side effects of the vaccine include pain and swelling at the injection site, fever, and a mild rash.